Mo Chunyan, Lou Xiran, Xue Jinfang, Shi Zhuange, Zhao Yifang, Wang Fuping, Chen Guobing
Medical School, Kunming University of Science and Technology, 727 Jingming South Road, Chenggong District, Kunming, 650500, China.
Department of Emergency Medicine, The First People's Hospital of Yunnan Province, 157 Jinbi Road, Xishan District, Kunming, 650034, China.
Gut Pathog. 2024 Aug 3;16(1):41. doi: 10.1186/s13099-024-00635-7.
Intestinal barriers play a crucial role in human physiology, both in homeostatic and pathological conditions. Disruption of the intestinal barrier is a significant factor in the pathogenesis of gastrointestinal inflammatory diseases, such as inflammatory bowel disease. The profound influence of the gut microbiota on intestinal diseases has sparked considerable interest in manipulating it through dietary interventions, probiotics, and fecal microbiota transplantation as potential approaches to enhance the integrity of the intestinal barrier. Numerous studies have underscored the protective effects of specific microbiota and their associated metabolites. In recent years, an increasing body of research has demonstrated that Akkermansia muciniphila (A. muciniphila, Am) plays a beneficial role in various diseases, including diabetes, obesity, aging, cancer, and metabolic syndrome. It is gaining popularity as a regulator that influences the intestinal flora and intestinal barrier and is recognized as a 'new generation of probiotics'. Consequently, it may represent a potential target and promising therapy option for intestinal diseases. This article systematically summarizes the role of Am in the gut. Specifically, we carefully discuss key scientific issues that need resolution in the future regarding beneficial bacteria represented by Am, which may provide insights for the application of drugs targeting Am in clinical treatment.
肠道屏障在人体生理学中起着至关重要的作用，无论是在稳态还是病理状态下。肠道屏障的破坏是胃肠道炎症性疾病（如炎症性肠病）发病机制中的一个重要因素。肠道微生物群对肠道疾病的深远影响引发了人们对通过饮食干预、益生菌和粪便微生物群移植来操纵它的极大兴趣，将其作为增强肠道屏障完整性的潜在方法。大量研究强调了特定微生物群及其相关代谢产物的保护作用。近年来，越来越多的研究表明，嗜黏蛋白阿克曼氏菌（Akkermansia muciniphila，A. muciniphila，Am）在包括糖尿病、肥胖、衰老、癌症和代谢综合征在内的各种疾病中发挥着有益作用。它作为一种影响肠道菌群和肠道屏障的调节剂越来越受到关注，并被公认为“新一代益生菌”。因此，它可能是肠道疾病的一个潜在靶点和有前景的治疗选择。本文系统总结了Am在肠道中的作用。具体而言，我们仔细讨论了未来以Am为代表的有益菌需要解决的关键科学问题，这可能为靶向Am的药物在临床治疗中的应用提供见解。
